康華生物(300841.SZ):股票7月21日起復牌
格隆匯7月20日丨康華生物(300841.SZ)公佈,2025年7月18日,公司收到控股股東、實際控制人王振滔先生及其一致行動人奧康集團有限公司(以下簡稱“奧康集團”)、持股5%以上股東濟南康悅齊明投資合夥企業(有限合夥)(以下簡稱“康悅齊明”)與上海萬可欣生物科技合夥企業(有限合夥)(以下簡稱“萬可欣生物”)簽訂的《股份轉讓協議》,及王振滔先生與萬可欣生物簽訂的《表決權委託協議》。根據《股份轉讓協議》,萬可欣生物擬使用自有資金和自籌資金以協議轉讓的方式受讓王振滔先生、奧康集團、康悅齊明合計持有的2,846.6638萬股公司股份,其中包括王振滔持有的350.1170萬股公司股份(佔剔除公司回購賬戶股份後總股本的2.6943%)、奧康集團持有的1,630.5468萬股公司股份(佔剔除公司回購賬戶股份後總股本的12.5478%)、康悅齊明持有的866.0000萬股公司股份(佔剔除公司回購賬戶股份後總股本的6.6643%)。本次轉讓價格爲每股65.0266元,股份轉讓價款合計爲人民幣185,108.8682萬元。根據《表決權委託協議》,股份轉讓後,王振滔先生將其個人持有的剩餘1,050.3517萬股公司股份(佔剔除公司回購賬戶股份後總股本的8.0829%)對應的表決權、提名和提案權、參會權獨家、無償且不可撤銷地委託給萬可欣生物行使。
本次股份轉讓完成及表決權委託後,萬可欣生物擁有公司表決權的比例爲29.9893%,公司控股股東將由王振滔先生變更爲萬可欣生物,因萬可欣生物無實際控制人,公司實際控制人將由王振滔先生變更爲無實際控制人。
根據《深圳證券交易所上市公司自律監管指引第6號——停復牌》等有關規定,經公司向深圳證券交易所申請,公司股票自2025年7月21日(星期一)開市起復牌。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.